The DMTF1 finding is compelling on its own, but the bigger story is what it represents in context. Three years ago, telomere lengthening in living humans was theoretical. Today there is a human clinical trial showing an FDA-approved pill does it, a Stanford study showing stem cells can be rejuvenated with a single molecular exposure, and a Harvard scientist standing at a global summit saying aging is reversible. The science did not inch forward. It accelerated. Do you think we are within 10 years of a clinically approved anti-aging therapy that measurably reverses biological age in humans?
positive
31
u/EmberMelodica
Ive been saying to people for a while, my generation will be the first to see immortality. Whether it's through biological advancements like this, or through technological replacement.
positive
16
u/Steambunsinvasion
Oh , dictators will live longer now…
negative
12
u/Voodizzy
Can this apply to dogs? ?
neutral
9
u/ahmtiarrrd
Cue billionaires ensuring they have exclusive access to therapies based on this breakthrough in 3... 2... 1...
negative
7
u/baycenters
DMTF1!1
neutral
5
u/poopin
Well, this would explain why billionaires are building bunkers.
negative
5
u/bardmalliard
So what vegetable am I supposed to eat to get this? ?
negative
4
u/Whatislifeabout24
Does this also work on TBI? ?
neutral
2
u/wvuroxx
Let’s goooo
positive
2
u/Mooseguncle1
No one here thinks this is how we wake up to a zombie outbreak?😷 ?
negative
1
u/OMGWTFBBQBRT
Stoked to see the story 2br02b come into fruition!
And its not going to make it in market. They don’t want you to get well just get hooked on pills
5
u/InterstellarKinetics
The immunosuppressive drug problem is the one that most people outside of transplant medicine do not fully appreciate. After an organ or cell transplant, the recipient's immune system has to be chemically suppressed for the rest of their life to prevent rejection. Those drugs work by broadly dampening immune activity, which means the patient is permanently more vulnerable to infections, cancers, and every other threat the immune system normally handles. For a 40 year old receiving a kidney transplant, the risk-benefit calculation is often clearly in favor of the transplant. For a child diagnosed with type 1 diabetes at age 8, a lifetime of immunosuppression starting in childhood is a genuinely difficult tradeoff.
What the MUSC team built is a way to get tissue-specific immune tolerance without systemic immunosuppression. The engineered Tregs are not broadly suppressing the immune system. They are precisely positioned at the transplanted beta cells using the CAR receptor and their job is specifically to protect those cells from immune attack. The immune system continues to function normally everywhere else in the body. That specificity is the engineering achievement that changes the risk calculus entirely.
The stem cell manufacturing side is equally important to understand at scale. Current islet transplants require beta cells from three to four organ donors per patient. There are not enough donors in the world to treat 1.5 million Americans with T1D, let alone the global population of approximately 8.4 million people with the disease. Lab grown beta cells that can be manufactured, quality-controlled, frozen, and shipped like any other pharmaceutical completely bypass that donor shortage. If the one-month durability in mouse models translates to multi-year durability in humans, this framework could be the actual end of daily insulin injections for the majority of people living with type 1 diabetes today. What other autoimmune conditions do you think this kind of targeted Treg bodyguard approach could be applied to next?
4
u/Difficult-Till5031
Hopefully this makes it out of trials. But I fear like a lot of other treatments it will be shelved or unaffordable.
When a bone breaks too severely to heal on its own, surgeons either take bone from somewhere else in your body creating a second wound or they put in a metal implant that your body never fully accepts. Swedish researchers just published a scaffold that does neither. It is implanted completely cell-free but it preserves the biological signals that tell your own stem cells to migrate in and build new bone using the structure as a blueprint. No donor cells, no rejection risk, no second wound site. If this scales to clinical use which current surgical procedure do you think it replaces first?
4
u/dunce_charming
Cool tech... I hope it can be scaled to normal use.
The ultrasound ranking is the buried finding that should alarm a lot of physical therapy patients. Ultrasound treatment for knee arthritis is common, frequently billed, and according to this analysis of 10,000 patients is the single least effective option of the twelve therapies tested. Meanwhile the two treatments that topped the list, knee braces and warm water exercise, are among the cheapest and most accessible interventions that exist. This paper is essentially saying the healthcare system has the cost-effectiveness relationship exactly backwards for knee osteoarthritis: the expensive high-tech options underperform and the cheap simple options lead. That gap between evidence and practice is what clinical guidelines are supposed to close.
This is not the absolute first sickle cell cure. FDA-approved gene therapies have succeeded since late 2023, but it is New York’s first, and Beauzile’s symptom-free status after 21 years underscores the therapy’s impact. The real bottleneck now is not efficacy, but the $3 million price tag and manufacturing capacity. Bone marrow transplants were the prior “cure,” but donor scarcity limited them to Approximately 20% of patients. Lyfgenia uses the patient’s own cells, solving that entirely.
Turning an erectile‑dysfunction drug into a life‑extending therapy for dying children is the kind of “repurposing” story that will resonate strongly with a general audience. The key detail to emphasize in comments is that sildenafil does not cure Leigh syndrome. What it appears to do is buy time and function by partially rescuing energy metabolism in neurons, giving affected kids more mobility, fewer seizures, and relief from the terrifying metabolic crises that can suddenly worsen the disease. That is still a massive change when the baseline is rapid neurodegeneration and early death. The orphan‑drug status and the planned SIMPATHIC trial are the concrete follow‑up milestones that will determine whether this becomes a standard treatment or remains a promising but niche intervention.
The 27 out of 28 number is the one that will anchor this story in the literature. Clinical trials for severe genetic diseases rarely produce outcome data this clean. The one non-responder in the cohort will be studied as carefully as the 27 successes because understanding what made that patient’s biology different is the key to predicting which future patients will respond. The donor registry disparity angle also deserves more attention than it typically receives in CRISPR coverage: bone marrow transplant as a cure for sickle cell disease has existed for decades but has functioned, in practice, as a cure primarily available to patients with a matched sibling donor, which skews heavily toward smaller families of European ancestry. An autologous therapy that requires no donor erases that disparity by design. If reni-cel moves through regulatory review with this data supporting it, the access question shifts from biology to economics, and that is a different and more solvable problem.